-+ 0.00%
-+ 0.00%
-+ 0.00%

Tvardi Plans 2027 IND Submission for TTI-109 in Inflammatory Bowel Disease

PUBT·11/19/2026 13:04:59
Listen to the news
Tvardi Plans 2027 IND Submission for TTI-109 in Inflammatory Bowel Disease
  • Tvardi Therapeutics plans to submit an investigational new drug application for oral STAT3 inhibitor TTI-109 in 2027 following supportive FDA feedback.
  • Ulcerative colitis remains the initial target indication; Crohn's disease is under evaluation as an additional indication.
  • Phase 2 initiation depends on FDA clearance of the application and additional funding.
  • Newly reported analysis of Phase 1 data supports potential sustained STAT3 inhibition at proposed doses, with minimal predicted effects on STAT1 and STAT5.
  • The findings suggest potential for a differentiated safety profile, but safety in inflammatory bowel disease patients remains unestablished.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190800PRIMZONEFULLFEED9880802) on November 19, 2026, and is solely responsible for the information contained therein.